Number of the records: 1  

TRAIL/APO2L inhibits myelodysplasia and myeloid leukemia progenitor growth while it does not affect normal progenitors in vitro and normal CD3+ cell repopulation in NOD/SCID mice

  1. 1.
    SYSNO ASEP0191427
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JOstatní články
    TitleTRAIL/APO2L inhibits myelodysplasia and myeloid leukemia progenitor growth while it does not affect normal progenitors in vitro and normal CD3+ cell repopulation in NOD/SCID mice
    Author(s) Plašilová, M. (CZ)
    Živný, J. (CZ)
    Jelínek, J. (CZ)
    Neuwirtová, R. (CZ)
    Čermák, J. (CZ)
    Nečas, E. (CZ)
    Anděra, Ladislav (UMG-J) RID
    Stopka, T. (CZ)
    Source TitleBlood - ISSN 0006-4971
    Roč. 98, č. 11 (2001), s. 3043
    Number of pages1 s.
    Languageeng - English
    CountryUS - United States
    KeywordsTRAIL ; leukemia ; apoptosis
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsIAA5052001 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    CEZAV0Z5052915 - UMG-J
    Annotationnormal hematopoieticĺ progenitors and stem cells.#LemfeldSusceptibility of primary malignant and normal hematopoietic progenitors to TRAIL-induced apoptosis was studied by clonogenic assays and by their repopulating potential after transplantation into NOD/SCID mice. In .I.E. coli ./I.produced extacellular part of human TRAIL (Aas 95-281) significantly reduced the number of myeloid colonies (CFU-GM) and clusters from patients with AML, CML, and MDS szndromes bud did not inhibited .I.in vitro ./I.and .I.in vivo ./I.growth of normal hematopoietic progenitors and stem cells.
    WorkplaceInstitute of Molecular Genetics
    ContactGabriela Marešová, maresova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2002

Number of the records: 1